Table 2.
Clinical and treatment details of the 15 patients who received palliative chemotherapy
| Patient | Age | Sex | PS | Stage | Site | CT | Cycles (n) | Palliative RT | Response | Survival (mo) |
| 1 | 80 | M | 1 | ES | Low | PE | 6 | No | PR | 16 |
| 2 | 58 | M | 1 | ES | Low | PE | 6 | No | PR | 12 |
| 3 | 67 | F | 2 | ES | Mid | P | 4 | No | PR | 9 |
| 4 | 80 | M | 3 | ES | Mid | P | 2 | No | UK | 1.5 |
| 5 | 59 | M | 1 | ES | Mid | PE | 2 | Yes | UK | 2 |
| 6 | 70 | F | 1 | ES | Low | PE | 4 | Yes | PR | 12 |
| 7 | 53 | F | 0 | ES | Low | CE | 6 | No | PR | 10 |
| 8 | 62 | F | 2 | ES | Mid | P | 4 | No | PR | 7 |
| 9 | 65 | M | 0 | ES | Low | PE | 4 | No | PR | 3.5 |
| 10 | 81 | F | 3 | ES | Low | None | 0 | No | NA | 1 |
| 11 | 84 | F | 2 | ES | Low | None | 0 | Yes | NA | 1 |
| 12 | 86 | M | 1 | LS | Low | P | 2 | Yes | SD | 14 |
| 13 | 75 | M | 1 | LS | Low | PE | 4 | No | PR | 3 |
| 14 | 72 | M | 0 | LS | Low1 | ECX/CE | 3/3 | No | SD | 13 |
| 15 | 75 | F | 1 | LS | Low | PE | 2 | No | PR | 5.5 |
1
Mixed pathology of small cell oesophageal cancer and squamous cell carcinoma. CE: Cisplatin and etoposide; CT: Chemotherapy; ED: Extensive stage; ECX: Epirubicin, cisplatin and capecitabine; F: Female; LD: Limited disease; M: Male; Mid: Middle; NA: Not applicable; Low: Lower; PE: Carboplatin and etoposide; PS: Performance status; PR: Partial response; RT: Radiotherapy; SD: Stable disease; UK: Unknown.